Phospholipid Analogues as Chemotherapeutic Agents Against Trypanosomatids. 2021

Evanthia Chazapi, and George E Magoulas, and Kyriakos C Prousis, and Theodora Calogeropoulou
Institute of Chemical Biology, National Hellenic Research Foundation, 48 Vas, Constantinou Av., 11635, Athens, Greece.

Neglected tropical diseases (NTDs) represent a serious problem in a number of countries around the world and especially in Africa and South America, affecting mostly the poor population which has limited access to the healthcare system. The drugs currently used for the treatment of NTDs are dated many decades ago and consequently, present in some cases very low efficacy, high toxicity and development of drug resistance. In the search for more efficient chemotherapeutic agents for NTDs, a large number of different compound classes have been synthesized and tested. Among them, ether phospholipids, with their prominent member miltefosine, are considered one of the most promising. This review summarizes the literature concerning the development of antiparasitic phospholipid derivatives, describing the efforts towards more efficient and less toxic analogues while providing an overview of the mechanism of action of this compound class against trypanosomatids. Phospholipid analogues are already known for their antiprotozoal activity. Several studies have been conducted in order to synthesize novel derivatives with the aim to improve current treatments such as miltefosine, with promising results. Photolabeling and fluorescent alkyl phospholipid analogues have contributed to the clarification of the mode of action of this drug family.

UI MeSH Term Description Entries
D010743 Phospholipids Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system. Phosphatides,Phospholipid
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D004364 Pharmaceutical Preparations Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form. Drug,Drugs,Pharmaceutical,Pharmaceutical Preparation,Pharmaceutical Product,Pharmaceutic Preparations,Pharmaceutical Products,Pharmaceuticals,Preparations, Pharmaceutical,Preparation, Pharmaceutical,Preparations, Pharmaceutic,Product, Pharmaceutical,Products, Pharmaceutical
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000981 Antiprotozoal Agents Substances that are destructive to protozoans. Schizonticides,Agents, Antiprotozoal
D058069 Neglected Diseases Diseases that are underfunded and have low name recognition but are major burdens in less developed countries. Neglected diseases include many tropical infectious diseases, e.g., HELMINTHIASIS; LEPROSY; LYMPHATIC FILARIASIS; ONCHOCERCIASIS; SCHISTOSOMIASIS; and TRACHOMA. Neglected Tropical Diseases,Disease, Neglected,Disease, Neglected Tropical,Neglected Disease,Neglected Tropical Disease,Tropical Disease, Neglected

Related Publications

Evanthia Chazapi, and George E Magoulas, and Kyriakos C Prousis, and Theodora Calogeropoulou
September 1988, Pharmaceutical research,
Evanthia Chazapi, and George E Magoulas, and Kyriakos C Prousis, and Theodora Calogeropoulou
November 2000, Drug news & perspectives,
Evanthia Chazapi, and George E Magoulas, and Kyriakos C Prousis, and Theodora Calogeropoulou
January 2001, Journal of medicinal chemistry,
Evanthia Chazapi, and George E Magoulas, and Kyriakos C Prousis, and Theodora Calogeropoulou
November 1988, Memorias do Instituto Oswaldo Cruz,
Evanthia Chazapi, and George E Magoulas, and Kyriakos C Prousis, and Theodora Calogeropoulou
January 2008, Current pharmaceutical design,
Evanthia Chazapi, and George E Magoulas, and Kyriakos C Prousis, and Theodora Calogeropoulou
January 2013, Current medicinal chemistry,
Evanthia Chazapi, and George E Magoulas, and Kyriakos C Prousis, and Theodora Calogeropoulou
May 2001, Current drug targets. Infectious disorders,
Evanthia Chazapi, and George E Magoulas, and Kyriakos C Prousis, and Theodora Calogeropoulou
August 2006, FEMS microbiology letters,
Evanthia Chazapi, and George E Magoulas, and Kyriakos C Prousis, and Theodora Calogeropoulou
January 2016, Medicinal chemistry (Shariqah (United Arab Emirates)),
Evanthia Chazapi, and George E Magoulas, and Kyriakos C Prousis, and Theodora Calogeropoulou
August 1975, Annals of the New York Academy of Sciences,
Copied contents to your clipboard!